Amanote Research
Register
Sign In
Grp78 as a Therapeutic Target for Refractory Head–neck Cancer With CD24−CD44+ Stemness Phenotype
Cancer Gene Therapy
- United Kingdom
doi 10.1038/cgt.2013.64
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Molecular Medicine
Molecular Biology
Date
November 1, 2013
Authors
C-C Chiu
L-Y Lee
Y-C Li
Y-J Chen
Y-C Lu
Y-L Li
H-M Wang
J T Chang
A-J Cheng
Publisher
Springer Science and Business Media LLC
Related search
Insulin-Like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer
Clinical Cancer Research
Cancer Research
Oncology
Salivary Soluble CD44: A Potential Molecular Marker for Head and Neck Cancer
Cancer Epidemiology Biomarkers and Prevention
Medicine
Epidemiology
Oncology
X-Linked FHL1 as a Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
Oncotarget
Oncology
The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer
Stem Cells International
Cell Biology
Molecular Biology
SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24- Phenotype
BMC Cancer
Cancer Research
Oncology
Genetics
Therapeutic Strategy for Cancer Immunotherapy in Head and Neck Cancer
Advances in Cellular and Molecular Otolaryngology
The CD44+/CD24-phenotype Is Enriched in Basal-Like Breast Tumors
Breast Cancer Research
Cancer Research
Oncology
The Molecular Chaperone GRP78/BiP as a Therapeutic Target for Neurodegenerative Disorders: A Mini Review
Journal of Genetic Syndromes & Gene Therapy
TIMP-3 as a Therapeutic Target for Cancer
Therapeutic Advances in Medical Oncology
Oncology
